Novo Nordisk’s "Triple G" drug UBT251 triggers nearly 20% weight loss in 24 weeks
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
Subscribe To Our Newsletter & Stay Updated